Last reviewed · How we verify

irbesartan, amlodipine and hydrochlorothiazide — Competitive Intelligence Brief

irbesartan, amlodipine and hydrochlorothiazide (irbesartan, amlodipine and hydrochlorothiazide) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic). Area: Cardiovascular.

marketed Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic) Angiotensin II type 1 receptor (AT1R), L-type calcium channels, sodium-chloride cotransporter Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

irbesartan, amlodipine and hydrochlorothiazide (irbesartan, amlodipine and hydrochlorothiazide) — Assistance Publique - Hôpitaux de Paris. This triple-combination antihypertensive reduces blood pressure through three complementary mechanisms: blocking angiotensin II receptors, inhibiting calcium influx into vascular smooth muscle, and promoting sodium and water excretion.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
irbesartan, amlodipine and hydrochlorothiazide TARGET irbesartan, amlodipine and hydrochlorothiazide Assistance Publique - Hôpitaux de Paris marketed Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic) Angiotensin II type 1 receptor (AT1R), L-type calcium channels, sodium-chloride cotransporter
olmesartan/amlodipine + hydrochlorothiazide, if necessary. olmesartan/amlodipine + hydrochlorothiazide, if necessary. Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company marketed Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic) Angiotensin II type 1 receptor (AT1R), L-type calcium channels, sodium-chloride cotransporter (NCC)
Losartan and amlodipine and hydrochlorothiazide Losartan and amlodipine and hydrochlorothiazide Hotel Dieu de France Hospital marketed Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic) Angiotensin II type 1 receptor (AT1R), L-type calcium channels, sodium-chloride cotransporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic) class)

  1. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  2. Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · 1 drug in this class
  3. Hotel Dieu de France Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). irbesartan, amlodipine and hydrochlorothiazide — Competitive Intelligence Brief. https://druglandscape.com/ci/irbesartan-amlodipine-and-hydrochlorothiazide. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: